Targeting Mps1 in combination with paclitaxel inhibits osteosarcoma progression by modulating spindle assembly checkpoint and Akt/mTOR signaling

LU LU1, YUHAI WANG2, JIAN CHEN3, YE LI3, QINGYANG LIANG3, FENG LI3, CHUANCHUAN ZHEN3 and KEGONG XIE1

1Department of Orthopedics, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi Zhuang Autonomous Region 533000; 2Academy of Orthopedics, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia Hui Autonomous Region 755000; 3Youjiang Medical University for Nationalities, Baise, Guangxi Zhuang Autonomous Region 533000, P.R. China

Received November 24, 2020; Accepted July 29, 2021

DOI: 10.3892/ol.2021.13058

Abstract. Osteosarcoma (OS) is the most common malignant bone tumor in children and adolescents and is characterized by early metastasis and frequent recurrence, which greatly affects patient prognosis and survival rates. However, the treatment of OS, its recurrence and subsequent metastasis is now at a clinical bottleneck. To explore new OS chemotherapeutic targets, investigate new therapeutic strategies and improve patient prognosis and survival rates, the roles of paclitaxel (PTX) and monopolar spindle kinase 1 (Mps1) in OS were investigated using in vivo and in vitro models. Mps1 expression was upregulated in OS samples and associated with patient survival times. Moreover, spindle assembly checkpoint (SAC) activation and upregulation of Akt/mTOR signaling were both positively associated with OS progression. PTX treatment significantly inhibited Mps1 expression, as well as migration of OS cells both in vitro. In addition, the combination of Mps1 knockdown and PTX treatment inhibited OS progression in vivo. Mps1 overexpression inhibited the expression of SAC markers and upregulated Akt and mTOR expression, while Mps1 knockdown had the opposite effect. Cells subjected to combined Mps1 knockdown and PTX treatment exhibited activation of SAC and inhibition of Akt/mTOR signaling compared with Mps1 knockdown or PTX treatment alone. Based on these observations, Mps1 inhibition combined with PTX treatment may represent a potentially effective strategy for the treatment of OS.

Introduction

Osteosarcoma (OS) is the most common primary malignant bone tumor, occurring primarily during childhood and adolescence. It is characterized by cell invasion and an early and high metastasis rate (1). Despite decades of OS research, surgery and chemotherapy are still the main treatment strategies for OS; the 5-year overall survival rate for OS patients is 70-80% (2). Moreover, the long-term survival rate is still low amongst patients with OS, due to the high frequency of metastasis and recurrence. Indeed, the 5-year recurrence survival rate is only 17.7% and is associated with age at diagnosis, disease severity, recurrence site and the time of recurrence (3). Therefore, OS treatment has entered a clinical bottleneck, with further breakthroughs required to improve patient prognosis (4). Thus, OS pathogenesis must be comprehensively unraveled, with a concomitant strategy towards the development of new therapeutic drugs.

In the 1960's, paclitaxel (PTX) was identified from the common Pacific Yew (Taxus chinensis). With its cytotoxic properties, the molecule attracted attention from researchers, who rapidly discovered its cytotoxic properties could be used for the development of new anticancer drugs (5). PTX promotes microtubule polymerization and stabilization in cells, where it regulates the spindle in mitosis, antagonizes the abnormal division of chromosomes and halts cells in the metaphase stage of mitosis, so as to reduce excessive proliferation and division of anticancer cells (6,7). Monopolar spindle kinase 1 (Mps1) was identified in 1991 in a yeast genetic screen of genes involved in spindle pole replication (8) and plays a central role in ensuring error-free chromosome segregation (9). Mps1 is critical for the recruitment of spindle assembly checkpoint (SAC) proteins to unattached centromeres, formation of the mitotic checkpoint complex (MCC) formation and inhibition of the multi-subunit E3 ubiquitin ligase (APC/C) (10). Inhibiting Mps1 activity leads to premature cell separation from mitosis,
resulting in severe chromosome mismatching, non-integer ploidy and eventually cell death (11). The inhibition of Mps1 using specific inhibitors reduces SAC signaling inhibition and returns cells to normal mitotic processes, underscoring its feasibility as a potential new anticancer strategy (11). Currently, Mps1 inhibitors are used in basic research, with excellent anti-cancer effects (12-14). Equally, the synergistic effects of Mps1 inhibitors combined with PTX has been shown to promote tumor cell death by enhancing cell division errors (15,16).

The SAC is the primary cell cycle control mechanism during mitosis, preventing chromosome mis-sets, and regulating the attachment of all sister chromatids to microtubules radiating from the poles of the spindle, thereby inhibiting cell entry into anaphase (17). The PTX regulation of cell mitosis appears to be inextricably linked to SAC regulation (18,19). A previous study showed that taxanes, as microtubule regulators, play apoptotic roles via SAC (20). Therefore, it is important to clarify the relationship between PTX and SAC and determine whether SAC regulation is mediated by Mps1.

The AKT/mTOR signaling pathway plays an important role in the regulation of normal cell growth, metabolism and survival. Activation or mutation of proteins involved in this pathway in human cells commonly occurs in different cancer types and causes a series of cell overgrowth syndrome with potential transit risk (21,22). In recent studies, the role of the AKT/mTOR pathway in OS regulation has been documented (23-25). AKT/mTOR signaling pathway has also been used to investigate the synergistic use of PTX in anticancer mechanisms and confirm that the regulation of AKT/mTOR pathway is expected to address the issues with PTX anti-tumor resistance (26,27). However, whether PTX inhibits OS cell migration and invasion through the AKT/mTOR pathway remains unclear. In the present study, in vivo and in vitro experiments were performed to demonstrate the role and mechanism of PTX and Mps1 with regard to OS.

Materials and methods

Sample and clinical data collection. Between January 2009 and August 2019 were selected and osteosarcoma specimens were collected; ii) patients have a clear pathological diagnosis; iii) patients with primary osteosarcoma; iv) patients were between 10 and 80 years old; v) patients included both men and women; vi) all patients received the same standard treatment regimen for osteosarcoma; and vii) the clinical cases and follow-up data of the patients were complete. The exclusion criteria were: i) Patients who had been treated with high-dose chemotherapy and other anti-tumor drugs before specimen collection; ii) cases complicated with other malignant tumors; iii) patients with severe heart disease; iv) liver and kidney failure before treatment; and v) perioperative death. A log-rank test was used to analyze Mps1 expression and survival rates of 50 clinical patients with OS data. Prior to sample collection, the study was approved by the Medical Ethics Committee of the Affiliated Hospital of Youjiang Medical University for Nationalities (approval no. YYFy-LL-2018-003). All patients or their parents/legal guardians (for patients <18 years old) provided written informed consent and agreed to the use of their samples in this study.

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA from adjacent normal and tumor tissue from patients with OS was isolated using TRizol® (Invitrogen; Thermo Fisher Scientific, Inc.) according to manufacturer’s instructions. Total RNA was then reverse transcribed to cDNA using the PrimeScript™ RT-PCR kit (Takara Bio, Inc.). The RT reaction conditions were 25°C for 10 min, 42°C for 30 min and 85°C for 5 min. Subsequently, qPCR was performed using SYBR-Green reagent (Yeasen Biotechnology Shanghai) using the following primers: i) Mps1 forward, 5'-CGCAGCTTT CTGTAGAAATGGA-3' and reverse, 5'-GAGCATCATTAGCGGAACAC-3'; and ii) GAPDH forward, 5'-CATGTACGT TGCTATCCAGGC-3' and reverse, 5'-CTCCTTAATGTACCGACGAT-3'. The GenBank accession number for Mps1 is NM_003318. PCR thermocycling conditions were as follows: 95°C for 2 min, 94°C for 15 sec, 60°C for 30 sec and 72°C for 20 sec, for a total of 40 cycles. Comparative quantification was assessed using the 2^ΔΔCq method (30), using GAPDH as the endogenous control.

Histopathology and immunohistochemistry (IHC). OS and normal adjacent tissue samples were collected during intraoperative surgical resection. Specimens were fixed in 10% formalin for 24 h at room temperature and embedded in paraffin, and were subsequently sectioned into 4-µm sections. Hematoxylin and eosin staining was performed as follows: The slides were incubated with hematoxylin in a staining jar for 10 min to stain the nuclei, and then were transferred to a staining jar with eosin solution for 3 min at room temperature. For IHC analysis, deparaffinized sections were pretreated with 0.4% pepsin for 60 min at 37°C, and endogenous peroxidase activity was blocked by treatment with 3% H2O2 for 10 min at 37°C and incubated with 50 µl of normal 5-10% goat serum blocking antigen for 15 min at room temperature. The following primary antibodies were used: Mps1 (cat. no. ab11108; 1:150; Abcam), MAD1 (cat. no. ab175245; 1:100; Abcam), Bub1 (cat. no. ab54893; 1:200; Abcam), AKT (cat. no. 9272S; 1:200; Cell Signaling Technology, Inc.) and mTOR (cat. no. ab2732; 1:150; Abcam). Tissue sections were incubated with primary antibodies at 4°C overnight, and then incubated with
horseradish peroxidase-labeled secondary antibody (1:200; 
cat. no. KXX0022; Dako; Agilent Technologies, Inc.) at 
room temperature for 1 h. 3',3'-Diaminobenzidine was used 
as a chromogen and the slides were incubated for 5 min. 
The sections were counterstained in Mayer's hematoxylin, 
washed again and dehydrated with ethanol and xylene prior 
to mounting. For IHC, brown particle staining was determined in 
OS tissues and normal tissues as a measure of positive staining. 
Tissue sections were assessed using an Olympus BX-41 light 
microscope to obtain high-resolution images (magnification, 
x200; Olympus Corporation). Aperio CytPlasma 2 software 
(Leica Microsystems, Inc.) was used to evaluate the intensity of 
IHC staining as follows: i) 0-25 points, (-); ii) 25-50 points, 
(+); iii) 50-75 points, (++); and iv) >130 points, (+++).

Cell culture. As for the selection of cell lines for constructing 
OS model in nude mice, 143B and MG63 cells are widely used 
OS cells. Several relevant studies have shown that 143B and 
MG63 cells are mostly used in antitumor experiments for the 
occurrence and development of OS (31,32). The human OS 
cells lines, 143B and MG63, were purchased from ScienCell 
Laboratories. Cells were cultured in high-glucose Dulbecco 
Modified Eagle’s Medium (DMEM; HyClone; Cytiva) supplemented 
with 10% fetal bovine serum (FBS; HyClone; Cytiva), and 100 U/ml penicillin/streptomycin (Gibco; Thermo 
Fisher Scientific, Inc.) Cells were maintained in a humidified 
atmosphere at 37˚C with 5% CO₂, MG63 and 143B OS cells 
treated with PTX were used for subcutaneous tumor-forming 
processes in nude mice. Briefly, cells were treated with 1 µmol/l 
PTX for 24 h then transfected with 1 µg short hairpin 
RNA (shRNA) plasmid targeting Mps1 or with 1 µg Mps1 
overexpression plasmid. The shRNA plasmid was constructed 
using the GV248 vector (Shanghai GeneChem Co., Ltd.). The 
overexpression plasmid (Mps1 Genbank ID, NM_003318) was 
constructed using the GV358 vector (Shanghai GeneChem 
Co., Ltd.). Both plasmids were transfected into cells using 
Lipofectamine® 2000 for 60 h (with the medium replaced every 
day) following the manufacturer's instructions (Invitrogen; 
Thermo Fisher Scientific, Inc.) and then maintained in a 
humidified atmosphere at 37˚C with 5% CO₂. Subsequent 
experiments were performed at 48 h post-transfection.

Nude mouse tumor model. BALB/c-nu nude mice (male, 
5-weeks-old; n=36; provided by Hunan Changsha Tianqin 
Biotechnology Co., Ltd.) were purchased from and housed in 
specific pathogen-free conditions (temperature 20-26˚C; 
relative humidity, 40-70%; 12-h light-dark cycle) at Youjiang 
Medical University for Nationalities. All animal experiments 
were approved by the institute's Animal Ethics Committee 
(approval no. 202000122). In an initial experiment, mice were 
inhaled with MG63 cells then mice divided into two groups 
(n=6/group): The control (saline group) or the PTX-treated 
group. In a separate experiment, mice were divided into 
four groups (n=6/group): i) Saline (control); ii) PTX-treated; 
iii) sh-MPS1-transfected and iv) PTX-treated and 
sh-MPS1-transfected. MG63 cells were harvested, counted, 
and resuspended in phosphate buffered saline (PBS) at a final 
concentration of 2x10⁶ cells/ml. Subsequently, 1x10⁶ cells 
in 50 µl PBS were injected into the armpits of mice using a 
26-gauge needle. Animal health and behavior were monitored 
at the same time every day and tumor volumes were measured 
in living nude mice every week until week 5 (endpoint). No 
mice died during the experiment. The tumors were removed 
from the mice and weighed 5 weeks after the transplantation. 
Sodium pentobarbital (150 mg/kg; 1%) was injected into the 
mice, which were then sacrificed using cervical dislocation. 
The death of the mice was confirmed by the cessation of 
breathing and cardiac arrest. Tumor volumes were calculated 
using the formula: Volume=0.2618 x L x W x (L + W), where W 
and L represent average tumor width and length, respectively.

Flow cytometry analysis of cell apoptosis. After cell 
transfection and PTX treatment, cells were collected for 
apoptosis assays and were resuspended at 10⁷ cells/ml. A volume of 100 µl was added to a 5-ml flow tube, and apoptosis 
measured using an PE Annexin V Apoptosis Detection kit 
(BD Biosciences) according to manufacturer's instructions. 
Cells were incubated at room temperature and in the dark for 
15 min. The data were acquired by flow cytometry using a 
FACScan (BD Biosciences) flow cytometer according to the 
manufacturer's instructions. FlowJo V10.0.7 (Tree Star, Inc.) 
was used for data analysis.

MTT assay. After digestion with 0.25% trypsin, 143B and 
MG63 cells were seeded in 96-well plates at 5x10³ cells/well, in 
DMEM containing 10% FBS, at a constant temperature of 
37˚C and 5% CO₂. The MTT assay was performed at 0, 12, 
24, 48 and 72 h. At the indicated timepoints, 20 µl MTT 
solution (5 mg/ml) was added to each well, and the plate placed 
into a 5% CO₂ incubator at 37˚C for 4 h. The supernatant 
was then discarded, 150 µl DMSO added to each well, and the plate 
incubated at room temperature for 10 min. Absorbance values 
were measured on an spectrophotometer at 490 nm. A growth 
curve was obtained by plotting the absorbance for each time 
point.

Scratch assay. The 143B and MG63 cells were seeded into 
6-well plates at a density of 1x10⁴ cells/well, to assess migration. 
When cells covered 80-90% of the dish, a sterile 100-µl pipette 
tip was used to mark four scratches in each well. Cells were 
washed twice in PBS and cultured in serum-free medium, 
and images were taken at 0 and 24 h (magnification, x4). 
Adobe Illustrator software (version CC 2019; Adobe Systems, 
Inc.) was used to measure the width of the scratches. Cell 
mobility=(0 h scratch width-48 h scratch width)/0 h scratch 
width x100. The assay was performed three times.

Transwell migration assay. Transwell migration assays 
were performed using a Transwell chamber (Corning, Inc.). The cells were prepared into a suspension using the 
medium and then inoculated into a six-well plate at a rate of 
1x10⁴ cells/well. Next, 150 µl suspended cells in serum-free 
medium were seeded into the upper Transwell chamber, and 
500 µl DMEM medium supplemented with 20% FBS was 
added to the lower chamber. After 24 h, the cells were fixed 
with 4% paraformaldehyde at room temperature for >10 min 
and stained with 0.5% crystal violet at room temperature for 
10 min. An inverted light microscope was used to examine 
the cells, and three random fields were observed to obtain 
average data.
Western blot analysis. Cells and tissues were lysed in 1X RIPA buffer (Beyotime Institute of Biotechnology) containing protease and phosphatase inhibitors. The protein extraction product was quantified by bicinchoninic acid assay (Beyotime Institute of Biotechnology). Proteins (50 µg) were loaded and separated on 10% SDS-polyacrylamide gels, then transferred to polyvinylidene difluoride membrane (Bio-Rad Laboratories, Inc.) using the wet transfer method. Each membrane was blocked with TBST (100 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.05% Tween-20) with 5% non-fat dried milk for 1 h at room temperature, then incubated with primary antibodies at 4˚C overnight. The membranes were then further incubated with HRP-conjugated secondary antibodies (anti-rabbit IgG, cat. no. 7074, 1:2,000; or anti-mouse IgG, cat. no. 7076, 1:2,000; both Cell Signaling Technology, Inc.) for 1 h at room temperature. Protein bands were visualized with ECL kit (Amersham; Cytiva) and the protein expression levels were analyzed using ImageJ software (v1.48; National Institutes of Health). The following primary antibodies were used: i) Mps1 (Abcam; cat. no. ab11108; 1:1,000); ii) MAD1 (Abcam; cat. no. ab175245; 1:1,000); iii) Bub1 (Abcam; cat. no. ab54893; 1:1,000); iv) Ki67 (Abcam; cat. no. ab231172; 1:1,000); v) mTOR (Abcam; cat. no. ab2732; 1:2,000); vi) AKT (Cell Signaling Technology, Inc.; cat. no. 9272S; 1:1,000); and vii) β-actin (Abcam; cat. no. ab8226; 1:5,000).

Statistical analysis. Graph Pad Prism version 6.0 software (GraphPad Software, Inc.) was used for statistical analysis and plotting. The data are presented as the mean ± SD.

Tukey’s post hoc test was used following one-way ANOVA. Three replicates were carried out for cell experiments and six for animal experiments. P<0.05 was considered significantly different.

Results

Mps1 expression is upregulated in OS samples and associated with patient survival rate. Mps1 expression in OS tissue was analyzed using HE staining and IHC. HE staining revealed that compared with normal tissue, OS tissue with obvious neoplastic osteoid tissue appeared in the background of malignant sarcoma cells, presenting typical neoplastic osteoid tissue, and OS tissue cells were full of distinctly heterogeneous neoplastic osteoblasts (Fig. 1A). IHC showed that Mps1 was localized to the cytoplasm and nuclei, although expression in OS tissue appeared higher than that in normal bone tissue (Fig. 1B).

Mps1 mRNA expression was analyzed using RT-qPCR in 50 clinical OS and adjacent normal tissue samples. Mps1 mRNA expression in OS tissue was significantly higher than that in adjacent normal bone tissue (Fig. 1C). In addition, a log-rank test was used to analyze Mps1 expression and survival rates of 50 clinical patients with OS. The overall survival rate of patients with high Mps1 expression was significantly lower than that of patients with low Mps1 expression (Fig. 1D). Taken together, these findings indicated that Mps1 expression was significantly upregulated in OS tissue and may be associated with overall survival of patients with OS.
Mps1 regulates SAC and Akt/mTOR signaling in OS. To determine the role of Mps1 and PTX in modulating OS, SAC and Akt/mTOR signaling were examined. IHC of OS tissue revealed that expression levels of the SAC components, MAD1 and Bub1 in OS tissues were lower than in adjacent tissues (Fig. 2A). In contrast, Akt and mTOR expression levels in OS tissue were significantly higher than those of adjacent tissue samples (Fig. 2B). These results suggested that SAC may be impaired, whereas components of Akt/mTOR signaling were upregulated in OS tissue. Thus, it was hypothesized that SAC and the Akt-mTOR signaling pathway may play important roles in OS development. Next, the expression of SAC and Akt/mTOR signaling markers were analyzed following genetic manipulation of Mps1 expression in vitro. 143B and MG63 cells were transfected with an Mps1 overexpression vector (OE-Mps1) or shRNA-Mps1 lentiviral vector. Western blot analysis confirmed overexpression of Mps1 in the OE-Mps1 group and significantly decreased Mps1 expression in the shRNA-Mps1 group. Compared with the respective controls, MAD1 and Bub1 expression were downregulated and AKT and mTOR expression upregulated in the OE-Mps1 group, whereas the shRNA-Mps1 group showed the opposite results (Fig. 2C and D). Thus, Mps1 may regulate SAC and Akt/mTOR signaling in OS.
PTX inhibits Mps1 expression, impairs migration of OS cells and promotes cell apoptosis. To investigate the impact of PTX on Mps1 expression, the OS cell lines, 143B and MG63, were treated with PTX for 12, 24, 48 or 72 h. Western blot analysis showed that Mps1 expression significantly decreased in cells cultured with PTX for 24 and 72 h (Fig. 3A). PTX also inhibited OS cell viability in a time-dependent manner (Fig. 3B). From the scratch assay data, it was observed that cell migration was inhibited by PTX treatment in both 143B and MG63 cells (Fig. 3C). Transwell results showed that PTX inhibited cell migration, and flow cytometry data showed PTX induced cell apoptosis (Fig. 3D-F) compared with the control. Next, MG63 cells treated with 1 µmol/l PTX were used to construct a nude mouse OS model, and tumor volume growth was recorded in nude mice over 5 weeks. Tumor histology and Mps1 expression in OS tissue was analyzed using HE staining and IHC, respectively. Tumor volumes of PTX exposed nude mice were significantly smaller than those of the control group (Fig. 3G). HE staining revealed no significant differences in the morphology of MG63 tumor tissues, and IHC confirmed a significant decrease in Mps1 expression (Fig. 3H) compared with the control. In summary, these data suggested that PTX downregulated Mps1 expression both in vitro and in vivo, inhibited OS cell proliferation, migration and promoted OS cell apoptosis.

PTX combined with Mps1 knockdown exhibits stronger anti-tumor effects in OS. To determine whether PTX in combination with Mps1 knockdown would have an improved effect against OS compared with PTX alone, the 143B and MG63 cell lines were transfected with the shRNA-Mps1 lentiviral vector and treated with PTX. The OS cells were divided into four groups: i) Control (saline); ii) shRNA-Mps1; iii) PTX alone; and iv) PTX + shRNA-Mps1. The MTT assay revealed that PTX + shRNA-Mps1 showed stronger cytotoxicity than PTX alone in OS cell, and this inhibitory effect increased with longer exposure times (Fig. 4A). Furthermore, cell migration was reduced, and the apoptosis rate was higher in PTX + shRNA-Mps1 cells compared with the shMps1 or PTX alone groups (Fig. 4B and C). The cells from different groups were then injected into nude mice. The tumor volume was smaller in mice in the PTX+ shRNA-Mps1 group compared with the shMps1 or PTX alone groups (Fig. 4D). Thus, these data indicated that PTX in combination with shRNA-Mps1 exerted a stronger antitumor effect on OS than shMps1 or PTX alone.

PTX in combination with Mps1 knockdown mediates SAC and Akt/mTOR signaling. To examine the effects of PTX in combination with Mps1 knockdown on SAC and Akt/mTOR signaling in OS, key biomarkers were examined in all groups. IHC results suggested that Mps1, Akt and mTOR expression levels were markedly lower, whereas those of MAD1 and Bub1 were higher in the shRNA-Mps1 group compared with the control group. The data from the PTX alone group were comparable with shRNA-Mps1 alone. In addition, the PTX + shRNA-Mps1 groups showed the lowest Akt and mTOR expression levels and the highest MAD1 and Bub1 expression levels (Fig. 5). In conclusion, PTX affected SAC, as well as Akt and mTOR expression. In addition, PTX in combination with Mps1 knockdown exerted a stronger effect than either condition alone on SAC, and the Akt/mTOR pathways.

Discussion

OS is caused by several factors, including aberrant differentiation of mesenchymal cells and tumor suppressor genes, oncogene activation, epigenetic events and cytokine production (33). Although OS therapeutics have improved after decades of research, long-term survival rates and prognosis for OS are still low due to early metastasis and high malignancy (2,34). These facts indicate the requirement for more mechanistic studies and the development of novel and more effective treatment strategies to elucidate disease pathogenesis, in order to improve patient survival times and prognosis. Currently, OS treatment strategies include neoadjuvant chemotherapies combined with surgical treatments and postoperative adjuvant chemotherapies (35). PTX is an effective anticancer drug that has been widely used to clinically combat several cancer types (36). PTX is currently used for the treatment of OS in preclinical research settings, and has shown promising clinical applications (37). In the present study, PTX exerted antitumor effects on OS, both in vitro and in vivo.

As a novel target and biomarker for cancer, Mps1 inhibitors effectively inhibit cancer cell proliferation and result in significantly improved survival (38). In the present study, high Mps1 expression was associated with poor patient survival. Mps1 was significantly upregulated in OS compared with normal adjacent tissues. Moreover, Mps1 modulation appeared to interfere with OS cell proliferation and development. Thus, to further investigate the anti-tumor effects of PTX in combination with Mps1 modulation in OS, several experiments were conducted, which showed that PTX combined with Mps1 inhibition exerted improved effects against OS compared with PTX alone. Mps1 is a bispecific protein kinase upstream of SAC that plays a key role in the precise separation of chromosomes during mitosis (13). In the present study, the downstream SAC markers, MAD1 and Bub1 were downregulated in OS tissue. Regulating Mps1 expression affected MAD1 and Bub1 expression, and was related to OS cell growth characteristics. Thus, the combination of PTX and Mps1 inhibition in OS cells appeared to upregulate SAC, and inhibit the oncogenic characteristics of OS cells. However, whether these mechanisms are directly or indirectly regulated by Mps1 to MAD1 and Bub1 has not yet been clearly established, and requires more research.

The Akt/mTOR pathway has been widely studied in various tumor cells, with its role in OS attracting considerable attention (23,24,39). In this study, Akt and mTOR expression levels were upregulated in OS tissue and affected by PTX treatment. Moreover, PTX downregulated the expression of Akt and mTOR to inhibit cancer-related OS characteristics. PTX combined with Mps1 knockdown significantly downregulated Akt and mTOR in OS cells.

The present study had some limitations. The occurrence and development of OS is not regulated by a single signaling pathway, but more likely regulated via multiple signaling pathways. The possible relationship between the Mps1 gene and other signaling pathways implicated in OS occurrence and
Figure 3. PTX inhibits Mps1 expression and migration of osteosarcoma cells and promotes their apoptosis. (A) Western blot analysis with semi-quantified results of Mps1 protein expression in 143B or MG63 cells after treatment with PTX for 0, 24 or 72 h. (B) Proliferation of 143B and MG63 cells after treatment with PTX for 0, 12, 24, 48 and 72 h. (C) Representative photomicrographs of wound healing assays in 143B and MG63 cells at 0 and 24 h (magnification, x100). (D) Transwell assay results of 143B and MG63 cells treated with PTX for 24 h. (E and F) Flow cytometry analysis of apoptosis in 143B and MG63 cells treated with PTX for 24 h. (G) Representative images and quantification of the volume of the xenograft tumors in the control and PTX-treated groups. (H) H&E and immunohistochemical staining of Mps1 in tumors from the control and PTX-treated groups. Scale bar, 100 µm. *P<0.05, **P<0.01, ***P<0.001 vs. control. Data are presented as the mean ± SD. Mps1, monopolar spindle 1 kinase; PTX, paclitaxel; OD, optical density; H&E, hematoxylin and eosin.
Figure 4. PTX combined with Mps1 knockdown exhibits strong anti-tumor effects in osteosarcoma cells. (A) Cell proliferation curve of 143B and MG63 cells in the con, sh-Mps1, PTX and PTX + sh-Mps1 groups. (B) Transwell assay results of 143B and MG63 cells in the con, sh-Mps1, PTX and PTX + sh-Mps1 for 24 h. (C) Flow cytometry analysis of apoptosis in 143B and MG63 cells in the con, sh-Mps1, PTX and PTX + sh-Mps1 groups. (D) Representative images and quantification of the volume of the xenograft tumors in the con, sh-Mps1, PTX and PTX + sh-Mps1 groups. *P<0.05, **P<0.01, ***P<0.001. Data are presented as the mean ± SD. Mps1, monopolar spindle 1 kinase; PTX, paclitaxel; sh, short hairpin RNA; OD, optical density; con, control.
Development were not examined. The failure to establish a lung metastatic model of OS in nude mice is also a limitation of this study. Due to the limitation of research conditions in Guangxi province, OS samples are relatively rare, so it is difficult to draw reliable conclusions by distinguishing different subtypes of OS. In addition, the relationship between the Mps1 gene and the degree of differentiation, type and tumor size of OS tumors were not statistically analyzed.

In summary, the present findings showed that PTX had effective antitumor effects, and that PTX combined with Mps1 inhibition improved the anti-OS effects. Mps1 inhibition significantly enhanced the tumor inhibition effects of PTX. This treatment strategy not only prevented OS cell proliferation and development in vitro, but also inhibited the growth of OS transplanted tumors in nude mice. Additionally, PTX in combination with Mps1 inhibition upregulated MAD1 and Bub1 expression, potentially enhancing SAC in tumor cells. Moreover, the Akt/mTOR pathway may also represent a target pathway potentially regulated by PTX and Mps1, and that Akt/mTOR pathway downregulation could be of great significance in inhibiting OS development. Therefore, PTX in combination with Mps1 inhibition may have broad application prospects for molecular therapeutics against OS.

Acknowledgements

Not applicable.

Funding

This study was supported by The National Nature Science Foundation of Guangxi (grant no. 2018GXNSFAA294091).
Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

KX conceived and designed the study. LL, YW and JC conducted the in vitro experiments and provided suggestions for the project. LL, YL and QL conducted the in vivo experiments. CZ and FL collected and analyzed experimental data. JC and YW drafted the manuscript and KX revised it. LL performed the analysis of data. All authors read and approved the final manuscript. LL and JC confirm the authenticity of all the raw data.

Ethics approval and consent to participate

This study was approved by The Medical Ethics Committee of the Affiliated Hospital of Youjiang Medical University for Nationalities (approval no. YYFy-LL-2018-003). All patients provided written informed consent and agreed to the use of their samples in this study. All animal experiments were approved by the institute’s Animal Ethics Committee of the Affiliated Hospital of Youjiang Medical University for Nationalities (approval no. 20200122).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Liu K, Ren T, Huang Y, Sun K, Bao X, Wang S, Zheng B and Guo W: Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis 8: e3015, 2017.
2. Smeland S, Bielack SS, Whelan I, Bernstein M, Hogendoorn P, Kralio MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, et al: Survival and prognosis with osteosarcoma: Outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 109: 36-50, 2019.
3. Spraker-Perlman HL, Barkauskas DA, Kralio MD, Meyers PA, Schwarz CL, Doski J, Gorlick R, Janeway KA and Isakoff MS: Factors influencing survival after recurrence in osteosarcoma: A report from the Children’s Oncology Group. Pediatr Blood Cancer 66: e27444, 2019.
4. Huang H, Han Y, Chen Z, Pan X, Yuan P, Zhao X, Zhu H, Wang J, Sun X and Shi P: ML264 inhibits osteosarcoma growth and metastasis via inhibition of JAK2/STAT3 and WNT/beta-catenin signalling pathways. J Cell Mol Med 24: 5652-5664, 2020.
5. Perdue RE Jr: Procurement of plant materials for antitumor screening. Cancer Treat Rep 60: 987-998, 1976.
6. van Vuuren RJ, Visagie MH, Theron AE and Joubert MS: Antimitotic drugs in the treatment of cancer. Cancer Chemotherapy Pharmacol 76: 1101-1112, 2015.
7. Weber BA: How Taxol/paclitaxel kills cancer cells. Mol Biol Cell 25: 2677-2681, 2014.
8. Winey M, Goetsch L, Baum P and Byers B: MPS1 and MPS2 novel yeast genes defining distinct steps of spindle pole body duplication. J Cell Biol 114: 745-754, 1991.
9. Pachis ST and Kops G: Leader of the SAC: Molecular mechanisms of Mps1/TTK regulation in mitosis. Open Biol 8: 180109, 2018.
10. Lauzé E, Stoelcker B, Luca FC, Weiss E, Schutz AR and Winey M: Yeast spindle pole body duplication gene Mps1 encodes an essential dual specificity protein kinase. EMBO J 14: 1655-1663, 1995.
11. Dominguez-Brauer C, Thu KL, Mason JM, Blaser H, Bray MR and Mak TW: Targeting mitosis in cancer: Emerging strategies. Mol Cell 60: 524-536, 2015.
12. Han Y, Wu Y, Xu Y, Guo W, Zhang N and Wang X: Molecular mechanism of point mutation-induced Monopolar spindle I (Mps1/TTK) inhibitor resistance revealed by a comprehensive molecular modeling study. PeerJ 7: e5990, 2019.
13. Mason JM, Wei X, Fletcher GC, Kiarash R, Broks R, Hodgson R, Beletskaya I, Bray MR and Mak TW: Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci USA 114: 3127-3132, 2017.
14. Choi M, Min YH, Pyo J, Lee CW, Jang CY and Kim JE: TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability. Br J Pharmacol 174: 1810-1825, 2017.
15. Maia ARR, Linder S, Song JY, Vaarting C, Boon U, Pritchard CEJ, Velds A, Huijnis J, van Tellingen O, Jonkers J and Medema RH: Mps1 inhibitors synergize with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division. Br J Cancer 118: 1586-1595, 2018.
16. Weng AM, Siemeister G, Koppitz M, Schulze V, Kosemund D, Klar U, Stocekigt D, Neuhau R, Lienau P, Bader B, et al: Novel Mps1 kinase inhibitors with potent antitumor activity. Mol Cancer Ther 15: 583-592, 2016.
17. Lara-Gonzalez P, Westhorpe FG and Taylor SS: The spindle assembly checkpoint. Curr Biol 22: R966-R980, 2012.
18. Chong T, Sarac A, Yao CQ, Liao L, Lyttle N, Boutros PC, Bartlett JMS and Spears M: Deregluation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer. J Ovarian Res 11: 27, 2018.
19. Sudo T, Nitta M, Saya H and Ueno NT: Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64: 2502-2508, 2004.
20. Mcgrogan B, Phelan S, Fitzpatrick P, Maguire A, Prencipe M, Brennan D, Doyle E, O’Grady A, Kay E, Furlong F and McCann A: Spindle assembly checkpoint protein expression correlates with cellular proliferation and shorter time to recurrence in ovarian cancer. Hum Pathol 45: 1509-1519, 2014.
21. Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong JK, Akbani R, Hadjipanayis A, et al: A Pan-cancer proteogenomic atlas of PI3K/AKT/mTOR pathway alterations. Cancer Cell 31: 820-832, 2017.
22. Keppler-Noreuil KM, Parker VE, Darling TN and Martinez-Agosto JA: Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies. Am J Med Genet C Semin Med Genet 172: 402-421, 2016.
23. Yue Z, Guan X, Chao R, Huang C, Li D, Yang P, Liu S, Hasegawa T, Guo J and Li M: Diallyl disulfide induces apoptosis and autophagy in human osteosarcoma MG-63 cells through the PI3K/Akt/mTOR pathway. Molecules 24: 2665, 2019.
24. Cheng DD, Li SJ, Zhu B, Zhou SM and Yang QC: EEFD1D overexpression promotes osteosarcoma cell proliferation by facilitating Akt-mTOR and Akt-bad signaling. J Exp Clin Cancer Res 37: 2018.
25. Zhao GS, Gao ZR, Zhang Q, Tang XF, Lv YF, Zhang ZS, Zhang Y, Tan QL, Peng DB, Jiang DM and Guo QN: TSSC3 promotes autophagy and apoptosis through inactivating the Src-mediated PI3K/Akt/mTOR and Akt-bad signaling. J Exp Clin Cancer Res 37: 2018.
26. Hu Y, Dong B, Chen D, Lin X, Zhang C, Liu Z, Han J, Li B, Hu Y, Dong B, et al: Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway. Cell Death Dis 9: 123, 2018.
27. Horan TC and Emori TG: Definitions of key terms used in the NNIS System. Am J Infection Control 25: 112-116, 1997.
29. Emori TG, Culver DH, Horan TC, Jarvis WR, White JW, Olson DR, Banerjee S, Edwards JR, Martone WJ, Gaynes RP, et al: National nosocomial infections surveillance system (NNIS): Description of surveillance methods. Am J Infect Control 19: 19-35, 1991.

30. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25: 402-408, 2001.

31. Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W, Yin H, Montag AG, Simon MA, Peabody TD, et al: An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 22: 319-329, 2005.

32. Pautke C, Schieker M, Tischer T, Kolk A, Neth P, Mutschler W and Milz S: Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res 24: 3743-3748, 2004.

33. de Azevedo JWV, de Medeiros Fernandes TAA, Fernandes JV Jr, de Azevedo JCV, Lanza DCF, Bezerra CM, Andrade VS, de Araújo JMG and Fernandes JV: Biology and pathogenesis of human osteosarcoma. Oncol Lett 19: 1099‑1116, 2020.

34. Ferguson JL and Turner SP: Bone cancer: Diagnosis and treatment principles. Am Fam Physician 98: 205-213, 2018.

35. Biazzo A and De Paolis A: Multidisciplinary approach to osteosarcoma. Acta Orthop Belg 82: 690-698, 2016.

36. Stage TB, Bergmann TK and Kroetz DL: Clinical pharmacokinetics of paclitaxel monotherapy: An updated literature review. Clin Pharmacokinetics 57: 7-19, 2018.

37. Houghton PJ, Kurmasheva RT, Kolb EA, Gorlick R, Maris JM, Wu J, Tong Z, Arnold MA, Chatterjee M, Williams TM and Smith MA: Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane®) by the pediatric preclinical testing program (PPTP). Pediat Blood Cancer 62: 1214-1221, 2015.

38. Xie Y, Wang A, Lin J, Wu L, Zhang H, Yang X, Wan X, Miao R, Sang X and Zhao H: Mps1/TTK: A novel target and biomarker for cancer. J Drug Target 25: 112-118, 2017.

39. Cai AL, Zeng W, Cai WL, Liu JL, Zheng XW, Liu Y, Yang XC, Long Y and Li J: Peroxiredoxin-1 promotes cell proliferation and metastasis through enhancing AktmTOR in human osteosarcoma cells. Oncotarget 9: 8290-8302, 2017.

This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.